Immutep

Immutep S.A. is a biopharmaceutical company developing immunotherapeutics in oncology. Our products include a T cell immunostimulatory factor (APC activator) for cancer chemo-immunotherapy and a therapeutic antibody for immune response modulation in cancer. The Company's technologies are based on the LAG-3 immune control mechanism which plays a vital role in the regulation of the T cell immune response.



» Corporate Information
© 2002 Immutep, S.A.
Press Release
01/2012 - Interview Frederic Triebel with PharmaTelevision
01/2011 - Immutep and GlaxoSmithKline sign licence agreement for IMP731, a novel therapeutic antibody for the treatment of autoimmune diseases
image Immutep S.A. announced today the execution of a licence agreement ...
09/2010 - Immutep announces final results in phase I/II chemoimmunotherapy trial in metastatic breast cancer.
image Clinical research paper describes IMP321’s potency in achieving ...
05/2010 - Immutep Announces Oral Presentation at ASCO Annual Meeting of IMP321 Final Results In Phase I/II Chemoimmunotherapy Trial
image Immutep S.A. announced today that the final results from its Phase ...
01/2010 - ImmuFact IMP321 doubles clinical response rate in first-line metastatic breast cancer
image Immutep S.A. announced today the final results from its Phase I/II ...